Showing results (1-10 of 155) with videos related to
Sort By:
Pageof 16
International Reviews of Immunology|January 1, 1997
Human IgG Fc receptorsI A Heijnen, J G van de WinkelJournal of Hematotherapy|October 1, 1995
A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeuticsI A Heijnen, J G Van de WinkelCancer Immunology, Immunotherapy : CII|January 22, 1998
Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibodyI A Heijnen, M J Glennie, J G van de WinkelBlood|November 9, 2000
Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphomaJ Honeychurch, A L Tutt, T Valerius, et al.Cancer Research|December 3, 1999
Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodiesG Huls, I A Heijnen, E Cuomo, et al.Current Opinion in Infectious Diseases|October 13, 2006
Fc receptor and complement receptor-mediated phagocytosis in host defenceG Vidarsson, J G van de WinkelBlood|May 1, 1996
FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivoM J van Vugt, I A Heijnen, P J Capel, et al.Cancer Research|February 15, 1997
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancerB Stockmeyer, T Valerius, R Repp, et al.Immunology Today|May 1, 1993
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implicationsJ G van de Winkel, P J CapelImmunology Today|September 1, 1990
Human Fc gamma receptor II: a standby receptor activated by proteolysis?W J Tax, J G van de WinkelPageof 16